Document YrggkNg5yGmL8wrY9jKyKLqME
R&S 002916
1803 BUILDING March 18, 1986
T. Burtch, 2030 WHDC W. Chen, Sarnia R. Cook, 1803 R. Davis, WSB S. Dombrowski, 2020 WHDC R. Egedahl, Sarnia P. Gehring, 2030 J. Norris, 1803 J. Lanham, 1803 R. Oubre, Oyster Creek C. Park, 1803 L. Rinzema, Horgen H. Verschuuren, Horgen P. Watanabe, 1803
In order to avoid duplicating of the entire report, only part of the preface and Tables 1, 2, 3 and 4A are attached from the 51 page report. The complete report will be filed in 1803 Building,
T. R. Torkelson
R&S 002917
CONFIDENTIAL REGISTER OF CASES OF ANGIOSARCOMA OF THE LIVER DUE TO EXPOSURE TO VINYL CHLORIDE - REVIEW DATE 1 JANUARY 1986
PREFACE: Acknowledgments, significant changes and comments
1. The new cases in the Register are the following :
France Germany UK
18 23,24, 25, 26, 2? 11, 12
2. There are amendments from the previous Register against the following cases: Germany 21, 22
US 36, 38
3. I would like to thank Dr De Sloover, Dr D M J Williams and Dr Friedel for informing me of new cases.
4. For the case corrections I would like to thank Dr Friedel, Mr J T Barr and Mr R W Frase.
5* For other corrections and information, thanks to Dr D Forman, Mr J T Barr, Mr T H Sutherland and Mr N F Humphry.
6. I should be very grateful if all recipients of the Register could continue to keep me fully informed of any new cases, or, if they should hear of other Companies who have acquired a case of ASL, it would be much appreciated if I could be notified by the appropriate person.
It is extremely helpful if new information is supplied in tabulated form, using the headings in the Register as far as possible.
7. 1 would like to thank the many people who have suggested research topics, and should be grateful if I could be kept up to date.
8. I shall be happy to supplyto any recipientof the Register a copy of the Paper "Exposureto Vinyl Chloride
andAngiosarcoma of theLiver:
a report ofthe Register of cases" by Dr David Forman,myself, DrJohn Stafford
and Sir Richard Doll, published in the British Journal of Industrial Medicine, November 1985 (42: 750-753)
Dr Brian Bennett M dical Department Imperial Chemical Industries pic Hillhouse Site P 0 Box 4 Thornton-Cleveleys Blackpool FY5 4QD England
February 1986
R&S 002918
Index Table Sequence Belgium Canada Czechoslovakia France Germany Italy Japan Norway Sweden UK USA Yugoslavia Incidence of Cases per annum
(Table 1)
IMPERIAL CHEMICAL INDUSTRIES PLC LIVER ANGIOSARCOMA CASES (REVIEW DATE - 1 JANUARY 1986)
WPX/ASL 2 - LANGIOCASES ,4
Page 1 2-3 4 5-8 9-14 15 16 17 18 19-21 22-28 29 30
ASL Case Numbers by year of Death (Table 6)
ASL Case Numbers by year of first exposure (Table 7)
Western Europe PVC Producers - Start-up Dates vs ASL Cases (Table 8)
USA PVC Producers - Start-up Dates vs ASL Cases (Table 9)
Canadian PVC Producers - Start-up Dates vs ASL Cases (Table 10)
East European PVC Producers - Start-up Dates vs ASL Cases (Table 11)
Japanese PVC Producers - Start-up Dates vs ASL Cases (Table 12)
South & Central American PVC Producers - Start-Up Dates (Table 13)
Australasian PVC Producers - Start-up Dates (Table 14)
Page 42 43 44 4 5+46 47 48 49 50 51
Distribution of Cases
by Country
(Table 2)
31
Pattern of Cases by
Factory
(Table 3)
32
Latency Periods (Table 4A)
33
Distribution of Latency Periods (Table 4B-4H)
34-40
Annual Geographical Incidence (Table 5)
41
Page
30
TABLE
1
(Review Date - l Jan 1986)
Incidence of ASL Cases Per Annua
By date of death
1955 ......................................................................................... 1
60
7 ......................................................................................... 1
8 .............................................................................. 0
9 ;......................................0
1960 ......................................................................................... 0
1 ......................................................................................... 1
21
3 ......................................................................................... 0
4 ......................................................................................... 2
5 ............................................................................................0
6 .............................................................................. 0
7 ......................................................................................... 1
8 ......................................................................................... 5
9 ......................................................................................... 3
1970 ......................................................................................... 2
1 ......................................................................................... 3
2 ......................................................................................... 5
3 ......................................................................................... 8
4 ......................................................................................... 5
5 ..........................................................................................11
6 .................................................................................11
79
8 ................................................................................. 10
9 ................................................................................. 5
1980
................................................................................. /0
1 ................................................................................. 5
2 .................................................................... 2
3 ................................................................................. 9
4 .................................................................................. 5
5 .......................................................................... ^_2
Total
117
N.B. 1 Does not include Italian 01 but does Include German 03.
i(Z 77*7
2 The 1977 total includes US case 24 which is a Cholanglosarcoma
3 The 1982 total does not Include US 33 and F 15 who are alive.
4 The 1983 total does not include US 36 who is alive.
J.
WPX/ASL 2 - LAHGIOCASES.35
\ R&S 002919
Page
31
Distribution of ASL Caaea by Country
TABLE
USA U Germany France UK Canada Sweden Yugoslavia Italy Czechoslovakia Japan Belgium Norway
35 AAA 26 AA 18 AAA 11 10
5 A AAA 4 AAAAA 4A 2 2 2 1
Total
120
(Review Date - 1 Jan 1986)
2 R&S 002920
* Omit ItOl - atypical caae of PVC bag extruder. ** Includes CE03 aerosol can filler. *** Includes case US 24 which was diagnosed as Cholanglosarcoma & US 33, and 36; and F 15 who are alive. **** Includes one monomer worker. ***** Includes two monomer workers.
i.e Western Europe North America Rest of World
67 45
8
WPX/ASL_2 - LANGIOCASES,36
Total 120 ------
Page 32
R&S 002921
Pattern of ASL Cases by Factory
(a) W Europe
TABLE 3
(Review Date - l Jan 1986)
Of the 67 cases in W Europe, 57 have occurred in clusters at 11 factories. Of the 26 German cases, 23 have occurred in clusters at A factories.
ASL Cases
Dynamlt, Troisdorf, Germany Chloe Chimie (Formerly BP), St Fons, France BP, Barry, UK Hacker, Burghausen, Germany Kemanord, Sundavail, Sweden PCUK, Brignoud, France CWH, Marl, Germany 1CI, Hillhouse, UK Solvay, Tavaux, France Lonza, Haldshut, Germany Solvay, Jeaeppe, Belgium
11 8 8 7 5 5 3 3 3 2 2
57
MB; There sre 32 pre 1962 PVC plants in H Europe; 18 of these have had ASL cases (Ref Table 8) (b) H America
Of the 45 cases in N America, 38 have occurred at four factories out of a total of 54 factories:- In N America 43 plants have not had ASL cases.
BFG, Louisville, US BFG, Shawinigan, Canada UCC, S Charleston Goodyear, Niagara
ASL Cases
14 10 10
4
38 NB: There are 28 pre 1962 PVC plants In N America; 11 of these have had ASL cases (Ref Tables 9 A 10) (c) Rest of World
The 8 A8L cases are believed to be In 1 cluster of 4 and 2 clusters of 2 cases. WPX/ASL_2 - LANGIOCASES,37
Page 33
R&S 002922
TABLE AA
(Review Date - 1 Jan 1986)
\
Latency Periods (Years from first Exposure to Diagnosis)
W Europe
Country Belgium
No of Cases 2
Total Years 35
Average 17.5
France
18 459 25.5
Germany
26 495 19.04
Italy
4 74 18.5
Norway
1 22 22
Sweden
5 122 24.5
N America
UK
11 254 23.09 67 1461 21.80
US 35 886 25.31
Rest of World
Canada
10 204 20.4 45 1090 24.22
Czechoslovakia
2
30 15.0
Japan
2 39 19.5
Summary
Yugoslavia
4 8
85 21.2 154 19.2
W Europe
67 1461 21.80
N America
45
1090
24.22
Rest of World
8 120
154 2705
19.2 22.54
* Of the countries with > 10 cases, France, UK and USA have an average latency period above world average, Germany and Canada below world average.
WPX/ASL_2 - LANCIOCASES,38
R&S 002923
^I ' v :.ation
\
Or A Rocs Adams, Air Products ^ Dr P N Anderson, Wilton
Jr I K K Bagshaw, Norsk Hydro Sr W C Barnes Jr, Monsanto, USA Or John T Barr, Air Products
Barrat, A.E.C.R.P. peter Baxter, J31AS M Benech, Naphtachimie Or B Bennett, ICI Hillhouse Dr P Bertazzl, Milan University Dr Bescne, Dynamit Nobel, Troisdorf Dr C Bishop, DMAS Dr D Bryson, Agricultural Div'n, ICI Mr David Burgess, ICI Americas Dr David Byren, Kemanord Jr J ! Carter, 3MAS Mr C Celia, Snichen Polimeri Mr M Chance, VCM Technical Manager. Mond Mr ? G Claus, AFHE Mr H Clayton, Norsk Hydro Dr J C Contassot, Chloe Chimie, St Fans Mr J G Davies, Sverberg (2) Dr De Sloover, Solvay Sir Richard Doll, Warden, Green College, Oxford Mr G Dupont, AFME Mr H Emminger, VKE Dr W Ernst, Nurnberg Dr H Falk, CDC Atlanta Dr D M Ferguson, ICI Americss Dr H P Friedel, Heidelberg . Prof I> Golberg, Durham, North Carolina, USA Dr R E Gosztonyi Jr, Tenneco Chemicals, Saddle Brook (NJ) Dr Walter D Harris, Uniroyal Inc Dr Donald W Hillman, Diamond Shamrock Dr Robert K Hinderer, KF Goodrich, Cleveland Mr J Hodgson, SMAS Dr A Hogg, Imperial Oil Ltd, Canada Dr J K Howard, Wellington, New Zealand Dr N F Humphry, Melbourne, Australia Mr J Jauvert, Chloe Chimie, Paris Mg^H R Jervis, Millbank
N Johnson, HF Goodrich ^^Pruce Karrh, Dupont
Dr R A Krueger, BF Goodrich Dr J P Leloine, Solvay Dr R W Laundrie, Akron, Ohio Mr J Lawrence, SPI Dr F I Lee, Victoria Hospital, Blackpool Prof W K Laibach, University of Bonn Dr G Levque, CDF Chimie, AZF Dr D A Levison, St. Bartholomew's Hospital, London Dr P Lewis, CIA Mr Lolivier, Solvay Dr J Lusaato, Atochem Prof R N M MacSween, Western Infirmary, Glaagow Dr J M Maillard, Luzern, Switzerland
Prof C Maitom, Bologna Prof Lo Martire, Medil-Anic-S, Milan Dr H Mattiusai, Montedison Mr D Middleton, Norsk Hydro Mr Mokka, Neste Oy Dr R Monteoano, larc, Lyons Dr A A Motti, Duperiai 3AIC, Buenos Aires Dr A Munn, Monsanto, Brussels
Mr M Munoz Mouton, Rio Rodano Mr S Nakamura, Japanese FVC Association Mr H G Olson, Louisians Dr J J O'Sullivan, ICI Mond Dr R Owen, TUC Dr G M Paddle, Central Medical Group, ICI Dr S Faglialunga, Montedison Dr Hans Popper, Mount Sinai Medical Centre Dr J Possberg, Wacker Dr A M Puech, Atochem Dr J Purdham, Canadian Centre for OHS Dr J Rambaud, 3P Recherches Mr P Hangr.ee, Norsk Hydro Dr ? Richard, Rhone Poulenc Dr J Ruty, Atochem Dr J Salg, Niosh, Cincinnati Dr R Saracci, larc, Lyons Dr M L Scheffers, DSH/CVMD, Holland Dr David Soronne, Diamond Shamrock Dr J Sigrist, Shell Chimie Dr Paul M Smith, Uandough Hospital Dr R Spirtas, NCX/NIH Bethesda Dr Carol Stack, CMA Washington Dr J Stafford, UK Mr Stahnecker, BASF Prof C H Tamburro, University of Louisville Dr Gary Ter Hear, Ethyl Corporation Dr B Terwiescfa, CWH Dr Gilles Theriault, McGill University Prof Dr Thieas, BASF Dr E Thiia Evens*, Norsk Hydro Dr W Tordoir, Shell Dr T H Torkelson, Dow Dr H J Van der Merwe, Sasolburg, South Africa Nr J S Wallace, Esso Chemical, Sarnia, Canada Mr H Walteaate, EF Goodrich, Cleveland Mr 5 0 Wejdling, Kemanord Dr D J Wheeler, ICI Hillhouse Mr S N Wheeler, UCC Dr J Whieton, ICI Hillhouse Mr K H White, Duperiai SAIC, Buenos Aires Dr D M J Willlass, BP Barry Dr K 5 Williamson, Central Medical Group, ICI Prof R Wilson, Harvard University Dr A P Wright, PEP Division, WUton Mr John Tork, Everberg
3B
(From : Dr B Bennett, Medical Department, Imperial Chemical Industries PLC, Hillhouse Site, PO Box A, Thoi-cton-drveleya, Blackpool FT5 Aqn, United Kingdom }
1A Jan 1985